10-K: XOMA Royalty Corporation Reports 2024 Results, Highlights Portfolio Growth and Strategic Acquisitions

XOMA Royalty Corporation's 2024 results reflect strategic portfolio expansion through acquisitions and royalty stream management, despite a net loss.

Summary

• XOMA Royalty Corporation reported a net loss of $13.8 million for the year ended December 31, 2024.
• The company's strategy focuses on acquiring economic rights to future milestone and royalty payments.
• Key acquisitions in 2024 included Pulmokine for $20.0 million and Kinnate, involving cash and a Contingent Value Right (CVR).
• The company is eligible to receive net royalties ranging from the low to mid-single digits on commercial sales and will retain a portion of future milestone payments from the Pulmokine acquisition.
• The company is eligible to receive 100% of the net proceeds received within five years of the closing date resulting from the license of exarafenib to Pierre Fabre, which was executed prior to the merger closing date.
• In October 2024, XOMA entered into a Royalty Purchase Agreement with Twist Bioscience, acquiring 50% of certain contingent payments related to Twists early-stage programs for $15.0 million upfront.
• Commercial payments from Roche's VABYSMO totaled $16.9 million in 2024.
• The company recorded credit losses on purchased receivables of $30.9 million, including $9.0 million related to the Aronora RPA, $14.0 million related to the Agenus RPA and $7.9 million related to the Talphera CPPA.
• The Board authorized a stock repurchase program of up to $50.0 million through January 2027; $13,000 of common stock was repurchased as of December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is reporting a net loss, it is actively growing its portfolio through strategic acquisitions and has secured significant commercial payments. The stock repurchase program also indicates a degree of confidence.

Positives

• Strategic acquisitions of Pulmokine and Kinnate expand the portfolio.
• New Royalty Purchase Agreement with Twist Bioscience adds potential revenue streams.
• FDA approval of OJEMDA triggers a $9.0 million milestone payment.
• Commercial payments from VABYSMO continue to provide significant revenue.
• Stock repurchase program signals confidence in the company's future.

Negatives

• Net loss of $13.8 million for 2024.
• Credit losses on purchased receivables totaled $30.9 million.
• Termination of the Organon License Agreement resulted in an impairment charge of $14.2 million in 2023.
• Alora Pharmaceuticals discontinued commercial sales of DSUVIA.

Risks

• Acquisitions may not produce anticipated revenues or income.
• Reliance on third parties for royalty and milestone payments.
• Volatility in the biotechnology industry can affect XOMA's partners and licensees.
• Dependence on licensees and royalty-agreement counterparties for royalty and milestone payments.
• Potential delays or failures in clinical development and regulatory approvals.
• Competition from other companies and products.
• Inability to protect intellectual property.
• Potential product liability claims.
• Healthcare reform measures and regulatory changes could adversely affect the business.
• The company may be required to register with the SEC as an investment company in accordance with the Investment Company Act of 1940.

Future Outlook

The company expects most of its future revenue and income to be based on payments it may receive for milestones and royalties associated with its assets as well as the periodic recognition of income under the EIR method.

Industry Context

The biotechnology and pharmaceutical industries are subject to significant technological change and intense competition. XOMA's royalty aggregator model faces competition from other companies and investment vehicles seeking to aggregate royalties or provide alternative financing to development-stage companies.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• A full comparison would require a deeper dive into the specific royalty rates, deal structures, and asset quality relative to peers like Royalty Pharma, Ligand Pharmaceuticals, and other royalty aggregators.
• Benchmarking against industry averages for royalty rates and milestone payments in similar therapeutic areas and development stages would be necessary for a comprehensive assessment.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic acquisitions and royalty stream management, but also risk of dilution from future equity issuances.
• Employees: Job security and potential for career growth within a growing company.
• Customers: No direct impact as XOMA does not directly sell products.
• Suppliers: Potential for increased business as XOMA expands its portfolio.
• Creditors: Ability to repay debt obligations through commercial payments from VABYSMO.

Next Steps

• Finalize licensing the Kinnate Pre-Clinical Assets in the first quarter of 2025.
• Continue to evaluate and pursue potential material contractual breaches against licensees and third parties.
• Continue to monitor assets and income for compliance under the 40 Act.

Key Dates